Fundz

MeiraGTx Holdings plc

New York, New York, United States · Biotechnology, Genetics, Health Care

MeiraGTx (Nasdaq: MGTX) is a vertically integrated, clinical-stage gene therapy company with six programs in clinical development and a broad pipeline of preclinical and research programs. MeiraGTx has core capabilities in viral vector design and optimization and gene therapy manufacturing, and a transformative gene regulation platform technology that allows precise, dose-responsive control of gen

Key facts

Headquarters
New York, New York, United States
Employees
51
Industries
Biotechnology, Genetics, Health Care
Status
Public (MGTX)
Website
meiragtx.com
LinkedIn
Company page

Recent activity at MeiraGTx Holdings plc

  • : MeiraGTx Appoints Alan M. Sebulsky as Class I Director
  • : MeiraGTx Enters Strategic Collaboration Agreement with Eli Lilly (date Fundz recorded it)
  • : SEC 8-K (5.02): On September 22, 2026, MeiraGTx Holdings plc's Board of Directors appointed Alan M. Sebulsky as a Class I director, effective September 23, 2026. His term will last until the Company's 2028 annual meeting of shareholders. Mr. Sebulsky will also serve on the Science and Technology Committee, following recommendation by the Company’s senior management. This appointment is strategic as it strengthens the company's governance and aligns with its focus on scientific innovations.
  • : SEC 8-K (1.01):
  • : SEC 8-K (1.01):
  • : SEC 8-K (1.01): On April 15, 2026, MeiraGTx Holdings plc and its subsidiary MeiraGTx Ocular UK Limited entered into an Asset Purchase Agreement with Janssen Pharmaceuticals, pursuant to which MeiraGTx purchased rights related to Janssen's gene therapy product for treating X-linked retinitis pigmentosa. The upfront cash purchase price is $25,000,000, with an additional contingent payment of $50,000,000 based on future regulatory approvals and sales milestones. Furthermore, MeiraGTx will pay royalties on future global net sales of the product, aiming to leverage these assets for further development and commercialization. JJDC, the investment entity of Johnson & Johnson, holds more than 5% of MeiraGTx's shares and has agreed to certain share transfer restrictions for twelve months following the closing.
  • : SEC 8-K (8.01): On April 16, 2026, the Company announced significant positive findings from its Phase 1 AQUAx clinical study of AAV-hAQP1, targeting grade 2/3 radiation-induced xerostomia. The treatment demonstrated safety with no serious adverse events, and maintained improvements in the Xerostomia Questionnaire (XQ) and Unstimulated Whole Saliva Flow Rate (UWSFR) over three years. With 63% of participants showing a substantial improvement in XQ scores, the Company sees AAV-hAQP1 as a potential first-in-class therapy for a condition affecting over 165,000 patients in the U.S. The estimated peak annual revenue potential for this treatment is projected at $3.7 billion globally, reflecting strong physician enthusiasm and favorable market conditions. The event date of the announcement is April 16, 2026, making this filing timely and relevant for stakeholders.
  • : SEC 8-K (1.01): On April 16, 2026, MeiraGTx Holdings plc entered into a material underwriting agreement with BofA Securities, Inc. and Goldman Sachs & Co. LLC for the issuance and sale of 11,111,111 ordinary shares at $9.00 per share. The total expected net proceeds from the offering are approximately $93.3 million, which will be used for general corporate purposes, including working capital and potential commercial launches of new treatments. The offering is scheduled to close on April 17, 2026, subject to customary closing conditions. The agreement includes standard representations, warranties, indemnification obligations, and termination provisions, ensuring protection for the underwriters and conditions favorable for the Company.
  • : SEC 8-K (1.01): On March 25, 2026, MeiraGTx Holdings plc entered into Amendment No. 4 to its Amended and Restated Notes Purchase Agreement with its subsidiaries, noteholders, and Perceptive Credit Holdings III, LP. This amendment includes the extension of the Maturity Date from August 2, 2026, to May 2, 2027, as well as a commitment to redeem $25,000,000 of the outstanding principal before June 30, 2026. Furthermore, the exercise price of certain warrants held by Perceptive was amended to $8.00 per share from previous prices of $15.00 and $20.00. These amendments are significant as they alter the financial obligations and terms of the Company's existing arrangements with key financing partners.
  • : SEC 8-K (1.01): On December 31, 2025, MeiraGTx Holdings plc entered into a Share Purchase Agreement with Perceptive Life Sciences Master Fund, Ltd. to purchase 2,300,000 of its ordinary shares at a price of $7.91 per share, totaling an aggregate of $18,193,000. This transaction was part of Perceptive Master Fund's year-end tax optimization activities. As part of the agreement, Perceptive Master Fund has committed to a 12-month lock-up period on the sale of these shares. Notably, Perceptive Master Fund owns more than 10% of the Company's outstanding shares and has ties to a significant $75 million note held by Perceptive Credit Holdings III, an affiliate, which consented to this share repurchase.

Dates are the day the event happened, taken from the announcement or SEC filing, unless a row says otherwise.

MeiraGTx Holdings plc funding history

DateRoundAmount
Aug 2022Debt FinancingUndisclosed

Leadership

  • Alan M. Sebulsky, Director
  • Oliver Peyer, Automation Scientist
  • Sarah Jeeves, Senior Human Resources Business Partner

Verified email and direct lines for MeiraGTx Holdings plc’s decision-makers are on Fundz. See plans or book a 15-minute walkthrough.

Employee benefit plans

MeiraGTx Holdings plc files 1 employee benefit plan with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.

MeiraGTx Holdings plc in the news

Companies similar to MeiraGTx Holdings plc

About MeiraGTx Holdings plc: questions and answers

What does MeiraGTx Holdings plc do?

MeiraGTx (Nasdaq: MGTX) is a vertically integrated, clinical-stage gene therapy company with six programs in clinical development and a broad pipeline of preclinical and research programs. MeiraGTx has core capabilities in viral vector design and optimization and gene therapy manufacturing, and a transformative gene regulation platform technology that allows precise, dose-responsive control of gen

Where is MeiraGTx Holdings plc headquartered?

MeiraGTx Holdings plc is headquartered in New York, New York, United States.

How many employees does MeiraGTx Holdings plc have?

MeiraGTx Holdings plc has about 51 employees.

Has MeiraGTx Holdings plc raised funding?

Yes. Fundz has recorded 1 funding event for MeiraGTx Holdings plc. The most recent, Debt Financing of Undisclosed, was in Aug 2022.

What is the latest news on MeiraGTx Holdings plc?

On Sep 23, 2026, MeiraGTx Appoints Alan M. Sebulsky as Class I Director

Is MeiraGTx Holdings plc a public company?

Yes. MeiraGTx Holdings plc is publicly traded under the ticker MGTX.

Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy

Fundz watches MeiraGTx Holdings plc across 18 signal types, from funding and M&A to exec moves and hiring.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.